CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both presentation and one-on-one investor meetings. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings.
Details
News Market Reaction – CRVO
On Sep 3, the day this news came out, CRVO closed 5.89% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:
H.C. Wainwright 27th Annual Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Presentation Date: Monday, September 8, 2025
Presentation Time: 2:00 – 2:30 PM ET
Webcast: https://journey.ct.events/view/b01e16a4-43fd-41b8-b4c0-2815213f7950
Morgan Stanley’s 23rd Annual Global Healthcare Conference
Format: 1x1 Investor Meetings
Conference Dates: September 8-10, 2025
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.